Biomerica (BMRA) Stock Analysis & AI Equity Report
Biomerica (BMRA) overview
Biomerica (BMRA) stock analysis and AI equity research. For financial year 2026, Valuatum's model shows revenue of USD 4.5m and operating profit of USD -5.3m; the year-end share price was 2.39 USD and market capitalisation was USD 7.6m. Biomerica is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Biomerica's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
About Biomerica
Biomerica develops, patents, manufactures, and markets diagnostic and therapeutic products. Its test kits analyze patient blood, urine, nasal, or fecal samples to help diagnose diseases, food intolerances, and other medical conditions. Products are sold worldwide to clinical laboratories and point-of-care settings, including physicians’ offices and over-the-counter channels. The company also provides contract development and manufacturing services.
Generate the Biomerica report
Biomerica is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Biomerica and represent financial year 2026. See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.
Analyst reports on Biomerica
Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.